Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

DNLI – Denali Therapeutics Inc.

Float Short %

10.14

Margin Of Safety %

Put/Call OI Ratio

0.3

EPS Next Q Diff

-0.05

EPS Last/This Y

-0.44

EPS This/Next Y

0.18

Price

15.48

Target Price

31.6

Analyst Recom

1.06

Performance Q

13.4

Relative Volume

1.69

Beta

1.22

Ticker: DNLI




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25DNLI13.670.170.001209
2025-07-28DNLI13.630.170.501210
2025-07-29DNLI13.610.170.001219
2025-07-30DNLI13.670.170.431228
2025-07-31DNLI13.830.171.601230
2025-08-01DNLI13.430.170.501241
2025-08-04DNLI14.430.170.101244
2025-08-05DNLI14.280.170.001250
2025-08-06DNLI14.350.170.001263
2025-08-07DNLI14.250.171.001264
2025-08-08DNLI13.980.170.191268
2025-08-11DNLI13.910.170.141287
2025-08-12DNLI13.240.181.001320
2025-08-13DNLI14.830.180.771324
2025-08-14DNLI14.450.19999.991342
2025-08-15DNLI14.710.190.001346
2025-08-18DNLI14.810.100.99916
2025-08-19DNLI14.810.340.001522
2025-08-20DNLI14.510.340.001535
2025-08-21DNLI15.230.300.451662
2025-08-22DNLI15.480.300.201677
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25DNLI13.67-24.7191.2-3.06
2025-07-28DNLI13.66-24.6166.7-3.06
2025-07-29DNLI13.61-24.6167.1-3.06
2025-07-30DNLI13.67-24.6164.3-3.06
2025-07-31DNLI13.83-24.6159.8-3.06
2025-08-01DNLI13.44-24.6182.2-3.06
2025-08-04DNLI14.44-24.6122.6-3.06
2025-08-05DNLI14.29-24.6172.3-3.06
2025-08-06DNLI14.36-24.6163.7-3.06
2025-08-07DNLI14.23-24.6171.0-3.06
2025-08-08DNLI13.96-24.6176.8-3.06
2025-08-11DNLI13.91-24.6168.0-3.06
2025-08-12DNLI13.22-24.6194.6-3.06
2025-08-13DNLI14.81-16.8109.2-3.06
2025-08-14DNLI14.44-16.8199.0-3.06
2025-08-15DNLI14.71-24.6174.5-3.00
2025-08-18DNLI14.81-24.6180.3-3.00
2025-08-19DNLI14.81-20.179.7-3.00
2025-08-20DNLI14.51-20.193.8-3.00
2025-08-21DNLI15.23-20.140.9-3.00
2025-08-22DNLI15.48-20.166.8-3.01
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25DNLI-2.474.7310.09
2025-07-28DNLI-2.474.5510.09
2025-07-29DNLI-2.474.5510.09
2025-07-30DNLI-2.474.5510.09
2025-07-31DNLI-2.474.5510.09
2025-08-01DNLI-2.474.5510.09
2025-08-04DNLI-2.473.6810.09
2025-08-05DNLI-2.473.6810.09
2025-08-06DNLI-2.473.6810.09
2025-08-07DNLI-2.473.6810.09
2025-08-08DNLI-2.473.6810.09
2025-08-11DNLI-2.473.7510.09
2025-08-12DNLI-2.463.7510.21
2025-08-13DNLI-2.463.7510.21
2025-08-14DNLI-2.453.7510.14
2025-08-15DNLI-2.483.7510.14
2025-08-18DNLI-2.483.6610.14
2025-08-19DNLI-2.483.6610.14
2025-08-20DNLI-2.483.6610.14
2025-08-21DNLI-2.483.6610.14
2025-08-22DNLI-2.483.6610.14
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.72

Avg. EPS Est. Current Quarter

-0.76

Avg. EPS Est. Next Quarter

-0.77

Insider Transactions

-2.48

Institutional Transactions

3.66

Beta

1.22

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

5

Fair Value

Quality Score

7

Growth Score

22

Sentiment Score

52

Actual DrawDown %

83.5

Max Drawdown 5-Year %

-87.7

Target Price

31.6

P/E

Forward P/E

PEG

P/S

P/B

2.2

P/Free Cash Flow

EPS

-2.81

Average EPS Est. Cur. Y​

-3.01

EPS Next Y. (Est.)

-2.82

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.69

Return on Equity vs Sector %

-71.3

Return on Equity vs Industry %

-58.4

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.05

EBIT Estimation

66.8
Denali Therapeutics Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 486
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
stock quote shares DNLI – Denali Therapeutics Inc. Stock Price stock today
news today DNLI – Denali Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch DNLI – Denali Therapeutics Inc. yahoo finance google finance
stock history DNLI – Denali Therapeutics Inc. invest stock market
stock prices DNLI premarket after hours
ticker DNLI fair value insiders trading